From: Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors
Total | Percentage | |
---|---|---|
Number of patient samples | ||
Total | 801 | 100 |
Age | ||
Mean ± SD | 62.25 ± 13.7 | |
Median (range) | 63 (22–90) | |
Tumor size | ||
<2 cm | 400 | 49.9 |
≥2–5 cm | 358 | 44.7 |
>5 cm | 43 | 5.4 |
Histology | ||
Ductal | 638 | 79.7 |
Lobular | 118 | 14.7 |
Other | 45 | 5.6 |
Tumor stage | ||
T1 | 413 | 51.6 |
T2 | 342 | 42.7 |
T3 | 38 | 4.7 |
T4 | 8 | 1 |
Grade | ||
I | 91 | 11.4 |
II | 502 | 62.7 |
III | 208 | 26 |
Nodal status | ||
N0 | 492 | 61.4 |
N1 | 226 | 28.2 |
N2 | 51 | 6.4 |
N3 | 32 | 4 |
Menopausal status | ||
Premenopausal | 167 | 20.8 |
Perimenopausal | 51 | 6.4 |
Postmenopausal | 583 | 72.8 |
Receptor status | ||
ER+ | 681 | 85 |
ER- | 120 | 15 |
PgR+ | 563 | 70.3 |
PgR- | 238 | 29.7 |
HER2+ | 110 | 13.7 |
HER2- | 691 | 86.3 |
HR+ | 688 | 85.9 |
HR- | 113 | 14.1 |
Receptor-defined subtype | ||
Luminal A-like | 510 | 63.7 |
Luminal B-like (HER2 positive) | 74 | 9.2 |
Luminal B-like (HER2 negative) | 104 | 13 |
HER2 positive (non-luminal-like) | 36 | 4.5 |
TNBC | 77 | 9.6 |